Proteon Therapeutics (PRTO) Research Coverage Started at Maxim Group

Maxim Group assumed coverage on shares of Proteon Therapeutics (NASDAQ:PRTO) in a research report released on Tuesday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $5.00 target price on the biopharmaceutical company’s stock.

Separately, Zacks Investment Research raised Proteon Therapeutics from a hold rating to a buy rating and set a $3.00 target price on the stock in a report on Wednesday, July 11th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Proteon Therapeutics presently has a consensus rating of Buy and an average price target of $3.50.

PRTO opened at $1.66 on Tuesday. Proteon Therapeutics has a 52-week low of $1.50 and a 52-week high of $2.90.

Proteon Therapeutics (NASDAQ:PRTO) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.08. Sell-side analysts anticipate that Proteon Therapeutics will post -1.16 earnings per share for the current year.

An institutional investor recently raised its position in Proteon Therapeutics stock. Renaissance Technologies LLC lifted its stake in shares of Proteon Therapeutics Inc (NASDAQ:PRTO) by 29.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 306,481 shares of the biopharmaceutical company’s stock after purchasing an additional 70,381 shares during the quarter. Renaissance Technologies LLC owned 1.73% of Proteon Therapeutics worth $751,000 as of its most recent SEC filing. Institutional investors own 50.56% of the company’s stock.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to improve hemodialysis vascular access outcomes.

Further Reading: Does the discount rate affect the economy?

Analyst Recommendations for Proteon Therapeutics (NASDAQ:PRTO)

Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply